Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Bi, Yonghua; Jiao, Dechao; Wang, Yang; Han, Xinwei; Ren, Jianzhuang

doi:10.1186/s12957-022-02696-x

Cited by 8 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for survival pro les, 1-year overall survival was 70.0%; 3-year overall survival was 37.5%; The median overall survival and PFS from rst treatment were 15.2 months and 5.2 months, respectively, which was similar patients using other beads [22,24,27]. Additionally, our study showed limited hepatic toxicity of DEB-TACE with irinotecan-eluting CB in GRLM patients, which is usually related to the chemotherapeutic drugs, cirrhosis history, and liver ischemia-reperfusion progress [28,29].…”

Section: Discussionsupporting

confidence: 54%

Efficacy and safety of irinotecan drug-eluting CalliSpheres beads in treating unresectable gastrointestinal cancer liver metastases

Guo²,

Jiao

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background Drug eluting beads transarterial chemoembolization (DEB-TACE) is considered as an effective and safe method in treating hepatocellular carcinoma. CalliSpheres beads (CB) is a novel microsphere product in China. Currently, few studies reported efficacy and safety of DEB-TACE with irinotecan-eluting CB in treating unresectable gastrointestinal cancer liver metastases (GRLM). This study aimed to evaluate the clinical outcomes of DEB-TACE with irinotecan-eluting CB in treating unresectable GRLM. Methods From May 2016 to May 2022, 28 patients with unresectable GRLM who were treated with DEB-TACE with irinotecan-eluting CB procedures were studied. Objective response rate (ORR) and disease control rate (DCR) were primary endpoints, Overall survival and progression-free survival (PFS) were the minor endpoints. Other indexes such as Child-Pugh class, systemic treatments and adverse events were assessed before or after procedure. Results ORR and DCR were 18.2% and 86.4%, respectively, at 1 month; were 27.8% and 61.1%, respectively, at 3 months; then were 21.4% and 50.0%, respectively at 6 months. As for survival profiles, 1-year overall survival was 70.0%; 3-year overall survival was 37.5%; the median overall survival and PFS were 15.2 months and 5.2 months, respectively. No severe adverse events were observed during and after DEB-TACE. The most common complication was abdominal pain (n = 13). Besides, nausea, fever, vomiting were observed in 5, 4 and 5 patients, respectively. Conclusions DEB-TACE with irinotecan-eluting CB is effective and safe, with good tolerance in treating unresectable GRLM.

show abstract

Section: Discussionsupporting

confidence: 54%

Efficacy and safety of irinotecan drug-eluting CalliSpheres beads in treating unresectable gastrointestinal cancer liver metastases

Guo²,

Jiao

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Further broad studies are required for more data on patient outcomes and efficacy. Arterial interventions such as TACE with raltitrexed eluting beads are studied to be safe and efficient in hepatic metastases due to gastric adenocarcinoma ( 158 ). In contrast to CRLM, the focus of arterial interventions in neuroendocrine liver metastases (NELM) is on the controlling the endocrine secretions ( 159 ).…”

Section: Other Hepatic Metastasesmentioning

confidence: 99%

Interventional radiological therapies in colorectal hepatic metastases

Vulasala,

Sutphin,

Kethu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Colorectal malignancy is the third most common cancer and one of the prevalent causes of death globally. Around 20-25% of patients present with metastases at the time of diagnosis, and 50-60% of patients develop metastases in due course of the disease. Liver, followed by lung and lymph nodes, are the most common sites of colorectal cancer metastases. In such patients, the 5-year survival rate is approximately 19.2%. Although surgical resection is the primary mode of managing colorectal cancer metastases, only 10-25% of patients are competent for curative therapy. Hepatic insufficiency may be the aftermath of extensive surgical hepatectomy. Hence formal assessment of future liver remnant volume (FLR) is imperative prior to surgery to prevent hepatic failure. The evolution of minimally invasive interventional radiological techniques has enhanced the treatment algorithm of patients with colorectal cancer metastases. Studies have demonstrated that these techniques may address the limitations of curative resection, such as insufficient FLR, bi-lobar disease, and patients at higher risk for surgery. This review focuses on curative and palliative role through procedures including portal vein embolization, radioembolization, and ablation. Alongside, we deliberate various studies on conventional chemoembolization and chemoembolization with irinotecan-loaded drug-eluting beads. The radioembolization with Yttrium-90 microspheres has evolved as salvage therapy in surgically unresectable and chemo-resistant metastases.

show abstract

“…A recent study evaluated TACE combined with percutaneous thermal ablation in LM larger than 3 cm ( 24 ) and achieved high local control rate with a local tumor progression rate at 12 months with 13%. In addition, an improvement in the results should be sought through the further development of the technology itself ( 25 , 26 ).…”

Section: Interventional Therapymentioning

confidence: 99%

Non-colorectal liver metastases: A review of interventional and surgical treatment modalities

Kniepeiss

Talakić²,

Portugaller³

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

Liver metastases (LM) occur in up to 90% either simultaneously with the diagnosis of the primary tumor or at a later time-point. While resection of colorectal LM and resection or transplantation of neuroendocrine LM is part of a standard therapy with a 5-year patient survival of up to 80%, resection of non-colorectal and non-neuroendocrine LM is still discussed controversially. The reason for it is the significantly lower survival benefit of all different tumor entities depending on the biological aggressiveness of the tumor. Randomized controlled trials are lacking. However, reviews of case series with ≥100 liver resections are available. They show a 5-year patient survival of up to 42% compared to only <5% in patients without treatment. Risk factors for poor survival include the type of primary tumor, a short interval between resection of the primary tumor and liver resection, extrahepatic manifestation of the tumor, number and size of the LM, and extent of liver resection. Overall, it has recently been shown that a good patient selection, the technical advances in surgical therapy and the use of a risk score to predict the prognosis lead to a significantly better outcome so that it is no longer justified not to offer liver resection to patients with non-colorectal, non- endocrine LM. Since modern therapy of LM is multimodal, the optimal therapeutic approach is decided individually by a multidisciplinary team consisting of visceral surgeons, oncologists, interventional radiologists and radiologists as part of a tumor board.

show abstract

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Cited by 8 publications

References 30 publications

Efficacy and safety of irinotecan drug-eluting CalliSpheres beads in treating unresectable gastrointestinal cancer liver metastases

Efficacy and safety of irinotecan drug-eluting CalliSpheres beads in treating unresectable gastrointestinal cancer liver metastases

Interventional radiological therapies in colorectal hepatic metastases

Non-colorectal liver metastases: A review of interventional and surgical treatment modalities

Contact Info

Product

Resources

About